IART Integra LifeSciences (IART) Q3 FY26 earnings call
Integra LifeSciences navigated Q3 FY26 with strong neurosurgery performance and record cash generation, which supported a successful debt refinancing and deleveraging. However, the quarter was marked by a larger-than-expected impact from the Cincinnati flood and uneven recovery in tissue reconstruction, leading to a revised full-year outlook. The company is focused on operational recovery, commercial execution, and new product initiatives, including the SurgiMend relaunch, to drive more consistent growth and further strengthen its financial position into 2027.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.